(Reuters) -Candel Therapeutics said on Wednesday its experimental immunotherapy for prostate cancer met the main goal of a late-stage trial, helping the company’s shares more than double in value in premarket trading.
The immunotherapy, CAN-2409, in combination with radiation therapy significantly improved disease-free survival in patients, compared to radiation alone, the company said.
Candel said it plans to discuss with the Food and Drug Administration regarding the therapy in intermediate-to-high-risk localized prostate cancer.
Over 100,000 men are diagnosed with prostate cancer every year in the U.S., the company said.
The company’s shares were up 176.8% at $12.76 in trading before the bell.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
Comments